Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 2 days ago
- 1 min read
26/06/2026
SKYRIZI® received US FDA approval for pediatric psoriatic disease (Ref)
AbbVie announced that the US FDA had approved SKYRIZI® (risankizumab-rzaa; IL-23 inhibitor) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis.
The approval was based on the Phase 3, OptIMMize-1/ NCT04435600 and OptIMMize-2/ NCT04862286 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg.
The safety profile in pediatric patients treated with SKYRIZI was consistent with the established safety profile in adults with plaque psoriasis.
Viridian Therapeutics announced US FDA approval and commercial launch of Lumvoa™ for Thyroid Eye Disease (Ref)
Viridian Therapeutics announced that the US FDA had approved Lumvoa™ (veligrotug-vvze; antagonist of IGF-1R) for the treatment of thyroid eye disease (TED).
Lumvoa was approved by the FDA under Priority Review and supported by the THRIVE (active TED) and THRIVE-2 (chronic TED) pivotal phase 3 clinical trials.
Viridian planned to launch Lumvoa immediately and expected to submit a BLA for subcutaneous eligrobart in Q1 2027.
